COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Y6VW
|
|||
Drug Name |
Fingolimod
|
|||
Synonyms |
2-Amino-2-(4-octylphenethyl)propane-1,3-diol
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Other Indication | Multiple sclerosis | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C19H33NO2
|
|||
Canonical SMILES |
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
|
|||
InChI |
1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
|
|||
InChIKey |
KKGQTZUTZRNORY-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 162359-55-9
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:63115
|
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04280588) Fingolimod in COVID-19 | |||
2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.